Vifor Pharma gains rights to Pfizer's Retacrit in the US dialysis market
Vifor Pharma, a company of the Swiss Galenica group (SIX: GALN), has further expanded its erythropoiesis stimulating agent (ESA) portfolio with the licensing of commercialization rights in the US dialysis market to Pfizer's (NYSE: PFE) Retacrit, a proposed biosimilar epoetin, in the field of nephrology.
Retacrit is a biosimilar to biotech major Amgen's (Nasdaq: AMGN) Epogen (epoetin alfa) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Procrit (epoetin alfa). Financial details of the transaction were not disclosed.
Pfizer subsidiary Hospira submitted a Biologics License Application (BLA) to the US Food and Drug Administration for Retacrit in December 2014. Retacrit is under review for the treatment of anemia associated with chronic kidney disease (CKD), renal failure as well as chemotherapy-induced anaemia. With access to Retacrit, once approved, Vifor Pharma will be positioned to also offer a short-acting ESA to the US dialysis market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze